Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh.
Hamermesh (pictured right), who joins from Locust Walk Partners where he served as senior vice president, will lead the business operations and corporate development strategies for the company.
He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.
Alongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
Julian Adams, chairman and chief executive officer of Gamida Cell, said: “We are pleased to welcome Josh and Paul to the Gamida Cell leadership team.
“Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic diseases.”